Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zevra Therapeutics

7.87
+0.08001.03%
Post-market: 7.870.00000.00%16:05 EDT
Volume:363.46K
Turnover:2.90M
Market Cap:430.33M
PE:-3.45
High:8.08
Open:7.82
Low:7.82
Close:7.79
Loading ...

Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves

TIPRANKS
·
14 Mar

Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
14 Mar

Zevra Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
13 Mar

Zevra Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
13 Mar

Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

GuruFocus.com
·
12 Mar

Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating

TIPRANKS
·
12 Mar

Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
12 Mar

Zevra Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
12 Mar

Zevra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Mar

Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours

MT Newswires Live
·
12 Mar

Zevra Therapeutics FY 2024 GAAP EPS $(2.28) Misses $(1.99) Estimate, Sales $23.600M Beat $20.514M Estimate

Benzinga
·
12 Mar

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Simply Wall St.
·
10 Mar

Zevra Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
08 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain

Simply Wall St.
·
04 Mar

Zevra Therapeutics: Strategic Growth and Financial Strength Drive Buy Rating

TIPRANKS
·
01 Mar

Zevra Launches New Disease State Awareness Campaign, ‘Learn Npc, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

THOMSON REUTERS
·
28 Feb

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

GlobeNewswire
·
28 Feb

BUZZ-Zevra Therapeutics rises on agreement to sell its FDA priority review voucher for $150 mln

Reuters
·
28 Feb